Odyssey Therapeutics, an immune-focused biotech company, has completed a $279 million initial public offering, rebounding after withdrawing its initial filing last year. The company, led by founder and CEO Gary Glick, is advancing a pipeline of drugs targeting autoimmune diseases and cancer.
The IPO adds to a recent string of sizable new biotech stock offerings, signaling renewed investor appetite for the sector. Odyssey's platform focuses on small-molecule drugs, including a preclinical candidate for inflammatory bowel disease and an earlier-stage asset for cancer immunotherapy.